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LETTERS TO THE EDITOR
Regarding “Prediction of 30-day mortality after
endovascular repair or open surgery in patients with
ruptured abdominal aortic aneurysms”
We read with interest the article by Dr Visser and colleagues.1
The Glasgow Aneurysm Score (GAS) was described in 1994 as
a tool for prognostic scoring in patients undergoing open repair of
either intact or ruptured abdominal aortic aneurysm (AAA). A
retrospective, multicentred, nonconsecutive sample of 500 pa-
tients undergoing aneurysm repair at general surgical units in
Glasgow between 1980 and 1990 was examined for risk factors
associated with death.2 Recently, this risk-scoring instrument has
been the subject of external validation. When applied to our own
series’ of both retrospective and prospective data on patients
undergoing attempted repair of ruptured AAA, the instrument
performed with moderate accuracy at best, and lacked discrimina-
tive ability in patients at high risk.3,4 Furthermore, when the
instrument is applied to endovascular repair of intact aneurysms,
the tool is found wanting too. Suboptimal performance was found
in a retrospective series from London, and the prospective data of
the DREAM trial noted poor validity in high risk patients.5,6
The poor performance of the GAS in contemporary series of
patients undergoing AAA repair is unsurprising given the origins of
the dataset with which it was modeled – patients treated with open
surgery in low-volume, nonspecialist, general surgical units more
than 20 years ago. To expect this risk-scoring instrument to
demonstrate validity, despite the existing reports questioning its
precision, on a series of patients undergoing open and endovascu-
lar repair of ruptured AAA is hopeful to say the least. However, to
attempt to refine the performance of the tool, so that it better fits
the reported data, seems intrinsically flawed.
The GAS was never intended for application in patients un-
dergoing endovascular aneurysm repair and lacks validity in high-
risk patients. Fifteen years from its conception, perhaps it is time to
acknowledge these deficiencies and accept that it is no longer fit for
purpose. Valuable data, such as those of the 4-A group, may be
better utilized to develop novel, original risk scoring instruments.
Elaine Yeap, MBChB
Andrew L. Tambyraja, MD
Roderick T. A. Chalmers, MD
Edinburgh Vascular Surgical Service
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
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Reply
We would like to thank Tambyraja and colleagues for their
valuable comments about our manuscript. It should be men-
tioned that, when developing a prognostic tool, two main
approaches could be followed. First, a new regression model can
be developed. Second, a former published regression model can
be updated. It is acknowledged from a statistical point of view
that updating a previously published model is preferred.1 There-
fore, we chose to update the previously published Glasgow
Aneurysm Score in stead of developing a new model. However,
we encourage further validation and updating of our prediction
rule.
Jacob J. Visser, MD, PhD
Marc R.H.M. van Sambeek, MD, PhD
Erasmus MC
Rotterdam, The Netherlands
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Regarding “Identification of a genetic variant
associated with abdominal aortic aneurysms on
chromosome 3p12.3 by genome wide association”
We read with interest the study by Elmore and colleagues,
which reported an association between a region on chromosome 3
and abdominal aortic aneurysm (AAA). We were intrigued to see if
this association was also present in our New Zealand AAA cohort.
An in silico validation was performed using 567 cases and 552
screened controls1 that have been genotyped using Affymetrix
Genome-Wide Human SNP Array 6.0. We could not replicate the
reported association with rs7635818. Nor was there any associa-
tion with neighboring SNPs. Nevertheless, we also examined SNPs
in the region of CNTN3, the nearest gene to the locus identified by
Elmore et al. Three SNPs within intron 2 showed suggestive
associations with AAA (Table), though these were of weak effect
and would not be considered significant when multiple testing is
taken into consideration.
While we do not discount the possibility that the suggested
chromosome 3 locus is truly associated with AAA, we would advise
caution with regard to this result. The lack of association with our
1246
large, geographically distinct, Caucasian population, the possibility
of population stratification in the Elmore et al study and low
statistical significance in the context of genome wide multiple
testing suggest that this region should not be considered as an AAA
locus at this time.
Gregory T. Jones, PhD
André M. van Rij, MBChB, MD, FRACS
Department of Surgery
Otago Medical School Dunedin
University of Otago
Dunedin, New Zealand
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Reply
We thank the investigators for their interest in our paper,1 and
would like to make several points regarding their observations.
First, their sample size is underpowered for a replication study of
the reported association. For an association with an odds ratio of
1.3 and minor allele frequency of 0.4, the statistical power is 0.45
(based on an allelic genetic model) at   0.05.2 Therefore, the
failure to replicate the association is not conclusive. Second, the
investigators do report a statistically significant association with
single nucleotide polymorphisms (SNP) in intron 2 of the CNTN3
gene. This supports our working hypothesis that a functional
variant in this region influences the phenotype. The differences in
specific genetic variants that are statistically associated with the
disease (and presumably a common functional genetic variant)
could reflect different haplotype structures in the study popula-
tions. Third, a difference in haplotype structure is further sug-
gested by our failure to replicate in our study population their
previously reported association of SNP rs5186 in the AGTR1 gene
with abdominal aortic aneurysm (AAA)3 (Table). Assuming the
reported odds ratio of 1.6,3 our sample size has 0.98 power to
detect an association (allelic genetic model,   0.05). Finally,
these considerations highlight some of the challenges of discover-
ing and validating the association of common genetic variants with
complex diseases. We are open to working collaboratively with
other investigators to overcome these challenges in addressing
important research questions.
James R. Elmore, MD
Melissa A. Obmann, DO
Helena Kuivaniemi, MD, PhD
Gerard Tromp, PhD
Glenn S. Gerhard, MD
David P. Franklin, MD
David J. Carey, PhD
Weis Center for Research
Geisinger Clinic
Danville, Penn
Amy M. Boddy, BS
Center for Molecular Medicine and Genetics
Wayne State University School of Medicine
Detroit, Mich
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Regarding “Incorporating outpatient venous
procedures into a vascular surgery practice”
The American Board of Phlebology (ABPh) agrees with many
of the points raised in the article by Shortell and Markovic.1 There
has been tremendous interest by physicians from a variety of
specialty backgrounds as a result of major new concepts and
significant innovations in the diagnosis and treatment of common
vein disorders. Duplex imaging has been critical to many of these
advances. Many vein procedures can now be done in an office-
based setting by using percutaneous or simple surgical procedures
and thus are being performed by primary care physicians, gynecol-
ogists, general surgeons, interventional radiologists, dermatolo-
gists, and physicians from other specialty backgrounds. Physicians
and surgeons from a variety of specialties have contributed to these
innovations.2-5
The mission of the ABPh, an independent nonprofit organi-
zation, is to improve the base of knowledge and experience of
medical practitioners and thus the care of patients related to venous
Table. SNP associations with AAA
Chr SNP marker Position AAA MAF Control MAF 2 P value Odds ratio 95% Confidence interval Gene region
3 RS7635818 74866166 0.4416 0.4437 0.010 0.9187 0.9913 0.839-1.172 intergenic
3 RS9876789 74628570 0.0565 0.0824 5.807 0.01596 0.6671 0.479-0.929 CNTN3 intron 2
3 RS6549604 74628467 0.0671 0.0915 4.545 0.03301 0.7147 0.524-0.974 CNTN3 intron 2
3 RS4076052 74623970 0.0212 0.0353 4.044 0.04434 0.5926 0.354-0.992 CNTN3 intron 2
AAA, Abdominal aortic aneurysm; Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
A total of 567 AAA cases and 552 elderly vascular disease (including AAA) free controls were compared.
Table. SNP rs5186 Association with AAA*
MAF case MAF control 2 P value
Odds
ratio
95% Confidence
interval
0.32 0.29 0.20 1.1 0.95-1.3
AAA, Abdominal aortic aneurysm; MAF, minor allele frequency; SNP,
single nucleotide polymorphism.
*704 AAA cases and 800 controls from the Geisinger Clinic population.
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